Safety and effectiveness of Niaspan when added sequentially to a statin for treatment of dyslipidemia

American Journal of Cardiology

Volumn 87, Issue 4, 2001, Pages 476-479

  Wolfe, Megan L ^a   Vartanian, Sara F ^a   Ross, Joyce L ^a   Bansavich, Lori Lynn ^c   Mohler III, Emile R ^a   Meagher, Emma ^a   Friedrich, Christopher A ^a   Rader, Daniel J ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NICOTINIC ACID;

ADULT; ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG MIXTURE; DRUG SAFETY; DYSLIPIDEMIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; ANTICHOLESTEREMIC AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERLIPIDEMIAS; MALE; MIDDLE AGED; NIACIN; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 0035865542     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(00)01410-7     Document Type: Article

References (18)

1. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport
2. Plasma triglyceride and coronary heart disease
3. Epidemiology of triglycerides: A view from Framingham
4. Triglyceride concentration and ischemic heart disease: An eight-year follow-up in the Copenhagen Male Study
5. Normal triglyceride levels and coronary artery disease events: The Baltimore Coronary Observational Long-Term Study
6. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: A meta-analysis of population-based prospective studies
7. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol
8. Pathophysiology and management of low high-density lipoprotein cholesterol
9. Niacin-induced hepatitis: A potential side effect with low-dose time-release niacin
10. Transient focal hepatic defects related to sustained-release niacin
11. Niacin-induced hepatotoxicity: Unusual presentations
12. Hepatotoxicity associated with sustained-release niacin
13. Treatment effect of niaspan, a controlled-release niacin, in patients with hypercholesterolemia: A placebo-controlled trial
14. Treatment of hyperlipidemia with combined niacin-statin regimens
15. Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia
16. Lovastatin, nicotinic acid, and rhabdomyolysis
17. Myolysis and acute renal failure in a heart-transplant recipient receiving lovastatin
18. Efficacy and safety of an extended-release niacin (niaspan): A long-term study